Clinical evolution of patients with lower extremity peripheral artery disease during the COVID-19 pandemic (the COVID-PAD study).

Background: The COVID-19 pandemic has led to significant disruptions in chronic disease care and forced people to stay at home. The effects of such issues on outpatients with lower extremity peripheral artery disease (PAD) remain unknown. Patients and methods: Single-centre, retrospective-prospective study conducted in a Swiss University Hospital. Patients with PAD were included between May 1 and July 31, 2020, with a follow-up visit at 12 months. Upon both visits, the Leriche-Fontaine PAD stage was recorded, and study participants underwent ankle-brachial index (ABI) calculation to assess limb perfusion. Functional capacities were assessed through the 6-minute walking and treadmill tests. Major adverse cardiovascular (MACE) and limb events (MALE) were recorded. Data collected during the pandemic were compared with the pre-pandemic period (January 1, 2019-April 30, 2020). Results: Overall, 259 patients were included. Mean age was 69 years and male sex was prevalent (69.1%). Odds of experiencing a degradation in PAD stage were lower during the pandemic than before (odds ratio [OR]: 0.43; 95% confidence interval [CI]: 0.21-0.87; p = 0.018). No significant difference was found between periods in terms of ABI trends. Both pain-free walking time at treadmill test (p = 0.003) and maximal pain intensity at 6-minute walking test (p = 0.001) significantly improved during the pandemic. Compared with the pre-pandemic period, during the pandemic patients were hospitalized less frequently (p = 0.028) and were less likely to undergo elective limb revascularization (p<0.001). No significant difference was found between periods in terms of MALE (p = 0.311), whereas non-fatal strokes were less frequently reported during the pandemic (p = 0.043). Conclusion: In a cohort of outpatients with PAD, we found no evidence of clinical deterioration during the pandemic compared with the pre-pandemic period, though rates of adverse events were nonnegligible in both periods. In case of future pandemics, patients with PAD should be encouraged to maintain an active lifestyle while being closely monitored to avoid clinical worsening.

[Venous thromboembolic disease : diagnostic pathways and follow-up]. / Maladie thromboembolique veineuse : démarche diagnostique et suivi.

Venous thromboembolism (VTE) is one of the leading causes of mortality and morbidity worldwide, and its diagnosis and risk stratification remain a challenge. Therapy and follow-up are also essential in the management of this pathology. The aim of this article is to summarize the most recent recommendations in the diagnostic pathway, risk stratification and follow-up of the more severe and frequent forms of VTE, pulmonary embolism and deep vein thrombosis of the lower limbs.

La maladie thromboembolique veineuse (MTEV) constitue l'une des principales causes de morbimortalité dans le monde. Le diagnostic et la stratification du risque demeurent des défis importants. La thérapie et le suivi sont également essentiels dans la prise en charge de cette pathologie. Cet article résume les recommandations les plus récentes dans la démarche diagnostique, la stratification du risque et le suivi des formes les plus graves et fréquentes de MTEV, l'embolie pulmonaire et la thrombose veineuse profonde des membres inférieurs.

[Management of aortic disease: the importance of an organized care network]. / Prise en charge de la maladie aortique : l'importance d'une filière des soins.

Pathologies of the aorta are a complex cardiovascular diseases requiring multidisciplinary management coordinated by specialized centers able to ensure adequate patient volume. This article describes the care pathways, based on the most recent data of the literature, to optimize the management of aortic diseases).

Les pathologies de l'aorte sont des maladies cardiovasculaires complexes nécessitant une prise en charge multidisciplinaire et cordonnée par des centres spécialisés pouvant assurer un volume adéquat de patients. Cet article décrit la filière des soins, basée sur les données les plus récentes de la littérature, pour optimiser la prise en charge de la maladie aortique.

[Who do you screen for an abdominal aortic aneurysm ?] / Chez qui effectuer un dépistage de l'anévrisme de l'aorte abdominale ?

Abdominal aortic aneurysm (AAA) represents an important public health problem. The early detection and treatment as well as follow-up of an AAA are important to reduce the high mortality rate associated with its rupture. Despite the decline of the prevalence of AAA in the last decades, the latest international recommendations have reaffirmed that screening in men remains cost-effective. In contrast, the data and recommendations for women are unclear. The best method for AAA screening is abdominal ultrasound. The aim of this paper is to present an up-to-date review of the indications for AAA screening based on the latest recommendations.

L'anévrisme de l'aorte abdominale (AAA) reste toujours un problème de santé publique malgré les progrès technologiques réalisés dans sa prise en charge. Le diagnostic précoce et le traitement ainsi que le suivi d'un AAA sont importants pour prévenir le taux de mortalité très élevé associé à sa rupture. Bien que la prévalence de l'AAA ait diminué ces dernières décennies, les dernières recommandations internationales ont réaffirmé qu'un dépistage chez les hommes reste rentable. En revanche, les données et les recommandations concernant la femme ne sont pas claires. L'examen de choix pour le dépistage des AAA est l'échographie abdominale. Cet article vise à mettre à jour les indications de dépistage de l'AAA en fonction des dernières recommandations.

[Venous thromboembolic disease during pregnancy : diagnosis, treatment and follow-up]. / Maladie thromboembolique veineuse et grossesse : diagnostic, traitement et suivi.

Venous thromboembolism is a leading cause of maternal morbidity and mortality with an overall incidence of 1-2 cases per 1000 pregnancies. The purpose of this article is to summarize more recent recommendations for the management of venous thromboembolism during pregnancy and post-partum period.

La maladie thromboembolique veineuse est l'une des principales causes de morbidité et mortalité maternelles avec une incidence globale de 1 à 2 cas pour 1000 grossesses. Le but de cet article est de résumer les recommandations les plus récentes concernant la prise en charge de la maladie thromboembolique veineuse pendant la grossesse et dans le post-partum.

Accuracy of the Ottawa score in risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism: a systematic review and meta-analysis.

In patients with cancer-associated venous thromboembolism, knowledge of the estimated rate of recurrent events is important for clinical decision-making regarding anticoagulant therapy. The Ottawa score is a clinical prediction rule designed for this purpose, stratifying patients according to their risk of recurrent venous thromboembolism during the first six months of anticoagulation. We conducted a systematic review and meta-analysis of studies validating either the Ottawa score in its original or modified versions. Two investigators independently reviewed the relevant articles published from 1st June 2012 to 15th December 2018 and indexed in MEDLINE and EMBASE. Nine eligible studies were identified; these included a total of 14,963 patients. The original score classified 49.3% of the patients as high-risk, with a sensitivity of 0.7 [95% confidence interval (CI): 0.6-0.8], a 6-month pooled rate of recurrent venous thromboembolism of 18.6% (95%CI: 13.9-23.9). In the low-risk group, the recurrence rate was 7.4% (95%CI: 3.4-12.5). The modified score classified 19.8% of the patients as low-risk, with a sensitivity of 0.9 (95%CI: 0.4-1.0) and a 6-month pooled rate of recurrent venous thromboembolism of 2.2% (95%CI: 1.6-2.9). In the high-risk group, recurrence rate was 10.2% (95%CI: 6.4-14.6). Limitations of our analysis included type and dosing of anticoagulant therapy. We conclude that new therapeutic strategies are needed in patients at high risk for recurrent cancer-associated venous thromboembolism. Low-risk patients, as per the modified score, could be good candidates for oral anticoagulation. (This systematic review was registered with the International Prospective Registry of Systematic Reviews as: PROSPERO CRD42018099506).

EANM guideline for ventilation/perfusion single-photon emission computed tomography (SPECT) for diagnosis of pulmonary embolism and beyond.

These guidelines update the previous EANM 2009 guidelines on the diagnosis of pulmonary embolism (PE). Relevant new aspects are related to (a) quantification of PE and other ventilation/perfusion defects; (b) follow-up of patients with PE; (c) chronic PE; and (d) description of additional pulmonary physiological changes leading to diagnoses of left ventricular heart failure (HF), chronic obstructive pulmonary disease (COPD) and pneumonia. The diagnosis of PE should be reported when a mismatch of one segment or two subsegments is found. For ventilation, Technegas or krypton gas is preferred over diethylene triamine pentaacetic acid (DTPA) in patients with COPD. Tomographic imaging with V/PSPECT has higher sensitivity and specificity for PE compared with planar imaging. Absence of contraindications makes V/PSPECT an essential method for the diagnosis of PE. When V/PSPECT is combined with a low-dose CT, the specificity of the test can be further improved, especially in patients with other lung diseases. Pitfalls in V/PSPECT interpretation are discussed. In conclusion, V/PSPECT is strongly recommended as it accurately establishes the diagnosis of PE even in the presence of diseases like COPD, HF and pneumonia and has no contraindications.

[Patient with lower extremity artery disease†: news in therapeutic approach]. / Artériopathie oblitérante des membres inférieurs†: nouveautés dans la thérapie médicamenteuse.

Prevalence of lower extremity artery disease (LEAD) is increasing with age, and there is a trend over the last decade towards an increase of LEAD patients. These patients are at increased risk of lower limb adverse event (MALE), but also at very high risk of major cardiovascular events (MACE). The best medical treatment, including medications, enable a reduction of this risk. Nevertheless, some patients will continue to develop MACE. New therapeutic molecules have been developed with randomized controlled trials, and showed a reduction of the -cardiovascular risk among these selected patients.

La prévalence de l'artériopathie oblitérante des membres inférieurs augmente avec l'âge, et, sur la dernière décennie, la tendance est à l'augmentation du nombre de patients atteints. Or ces patients sont à risque de développer des complications vasculaires locales, mais aussi des complications cardiovasculaires dans d'autres ­territoires. La prise en charge optimale, qui comporte un volet ­médicamenteux, permet de réduire le risque cardiovasculaire de ces patients. Chez certains, cependant, il persiste un risque résiduel. De nouvelles classes thérapeutiques ont été développées au travers d'essais cliniques contrôlés, randomisés, en double aveugle et ont permis de mettre en évidence une réduction complémentaire du risque cardiovasculaire chez ces patients.

[Lower extremity peripheral artery disease†: local and systemic complications]. / Artériopathie oblitérante des membres inférieurs†: complications locales et systémiques.

Lower extremity peripheral artery disease can lead to local complications but also to complications in other vascular areas, stressing the systemic impact of the atheromatous disease. The current concepts of MALE (Major Adverse Limb Events) and MACE (Major Adverse Cardiac Events) encompass these risks. The systemic vascular complications, as well as the ones at lower extremities, are associated with significant morbidity and mortality. An optimal therapeutic management and healthy lifestyle, such as regular exercise, are crucial to limit the risk of unfavorable progression of the arterial disease. A close collaboration between the general practitioner and the angiologist is a key to adequate initial management and follow-up of the patients.

L'artériopathie oblitérante des membres inférieurs (AOMI) est associée à des complications locales et dans d'autres territoires vasculaires, témoignant du caractère généralisé de la pathologie athéromateuse. Les notions récentes de MALE (major adverse limb events) et MACE (major adverse cardiac events) reflètent cette approche conceptuelle de la maladie athéromateuse. Les complications vasculaires systémiques et spécifiques aux membres inférieurs sont à l'origine d'une morbi-mortalité significative. Une prise en charge optimale médicamenteuse et d'hygiène de vie, en particulier une activité physique régulière, sont fondamentales pour limiter les risques d'évolution défavorable de la pathologie artérielle. La collaboration étroite entre le médecin interniste-généraliste et l'angiologue est à la base de la prise en charge initiale et du suivi des patients.

[Thromboangiitis obliterans: notions for practice]. / Thromboangéite oblitérante :notions pour la pratique.

Thromboangiitis obliterans is an occlusive vasculopathy affecting small- and medium-size arteries. It can result in severe ischemic status. Thrombophlebitis can be associated. The exact etiology has still to be elucidated. Smoking is the main contributing factor. Diagnosis is based on clinic and paraclinic context, as well as exclusion of other vascular pathologies. Its management consists in complete smoking cessation and instauration of vasodilator treatment. Revascularization is an option that has to be evaluated on a case by case basis. New promising therapeutic approaches are emerging.

La thromboangéite oblitérante se caractérise principalement par une atteinte occlusive des artères de petit et moyen calibres, pouvant mener à un tableau clinique ischémique grave. Une thrombophlébite peut y être associée. L'étiologie exacte n'est pas encore connue. Le tabagisme est le facteur de risque prépondérant. Le diagnostic se base sur les contextes clinique et paraclinique, ainsi que l'exclusion d'autres pathologies vasculaires. La prise en charge consiste en l'arrêt définitif du tabagisme et l'introduction de traitements vasodilatateurs. Les options de revascularisation sont à discuter de cas en cas. De nouvelles modalités thérapeutiques semblent prometteuses.

Prevalence and risk factors for venous thromboembolic complications in the Swiss Inflammatory Bowel Disease Cohort.

OBJECTIVE: Inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), is associated with the occurrence of venous thromboembolism (VTE) such as deep vein thrombosis (DVT) and pulmonary embolism (PE). We aimed to assess the prevalence and associated risk factors for VTE in a large national cohort of IBD patients. MATERIAL AND METHODS: Data from patients of the Swiss IBD Cohort Study (SIBDCS) enrolled between 2006 and 2013 were analyzed. RESULTS: A total of 2284 IBD patients were analyzed of which 1324 suffered from CD and 960 from UC. VTE prevalence was 3.9% (90/2284) overall and 3.4% (45/1324) in CD patients (whereof 2.4% suffered from DVT and 1.5% from PE) and 4.7% (45/960) in UC patients (whereof 3.2% suffered from DVT and 2.4% from PE). Median disease duration in CD patients with VTE was 12 years [IQR 8-23] compared to eight years [3-16] in CD patients without VTE (p = 0.001). Disease duration in UC patients with VTE was seven years [4-18] compared to six years [2-13] in UC patients without VTE (p = 0.051). Age at CD diagnosis ≥40 years (OR 1.851, p = 0.073) and disease duration >10 years (OR 1.771, p = 0.088) showed a trend to be associated with VTE. In UC patients, IBD-related surgery (OR 3.396, p = 0.004) and pancolitis (OR 1.927, p = 0.050) were significantly associated with VTE. CONCLUSIONS: VTE are prevalent in CD and UC patients. Pancolitis and UC-related surgery are significantly associated with VTE in UC patients.

Accuracy of in-patients ankle-brachial index measurement by medical students.

BACKGROUND: Ankle brachial index (ABI) is a first line non-invasive screening tool for peripheral arterial disease (PAD) in at risk populations. The need to extend ABI use in large population screening has urged its use by professionals other than vascular physicians. As advocated by the American Heart Association, ABI teaching is part of medical curriculum in several countries. We determine accuracy in ABI measurement by trained medical students compared with an experienced angiologist. METHODS: Twelve 6th year medical students underwent 9 days of training at Lausanne University Hospital. Students and an experienced angiologist, blinded to students' results, screened consecutive hospitalised patients aged ≥ 65 or ≥ 50 with at least one cardiovascular risk factor during a 6-week period. RESULTS: A total of 249 patients were screened of whom 59 (23.7%) met the inclusion criteria. Median age was 80, 45.8% were women, and 6.8% were symptomatic. In total, 116 ABIs were available for analysis. Agreement between students and angiologist was moderate with a k-value of 0.498 (95% confidence interval: 0.389-0.606). Overall accuracy and precision of PAD screening performed by students showed sensitivity of 73.2% and specificity of 88.0%. Positive and negative predictive values were 76.9% and 85.7%, respectively; positive and negative likelihood ratios were 6.3 and 3, respectively. CONCLUSIONS: A nine day training program on ABI measurement is not sufficient for inexperienced medical students to achieve an acceptable diagnostic accuracy in detecting PAD in at risk populations.

[Relevance of contrast ultrasound with microbubbles in vascular medecine]. / Intérêt de l'échographie de contraste aux microbulles en médecine vasculaire.

Application of ultrasound contrast media has become a standard in diagnostic imaging in cardiology and in the characterization of focal lesions in multiple organs, especially of the liver. In the past years there was a growing body of evidence for their usefulness in vascular medicine. The development of contrast media, microbubbles with a stabilizing envelope and filled with gaz, small enough to pass through pulmonary capillaries made real-time imaging of organ perfusion possible. Ultrasound contrast media are rapidly eliminated by exhalation and can safely be administered to patients with renal failure. The objective of this review is to describe the basic principles of ultrasound contrast imaging and to inform about vascular applications of contrast ultrasound.

Les produits de contraste échographiques sont utilisés depuis de nombreuses années en imagerie diagnostique et font partie de l'arsenal de l'investigation cardiologique et des lésions focales de multiples organes, surtout hépatiques. Leur emploi dans le domaine vasculaire est plus récent et permet une meilleure imagerie de la vascularisation que l'écho-Doppler natif. Le développement de microbulles de gaz enrobées d'une enveloppe et franchissant les capillaires pulmonaires a permis de visualiser la perfusion des organes en temps réel. Elles sont rapidement éliminées par exhalation et peuvent être utilisées chez des patients souffrant d'insuffisance rénale sévère. Cette revue a pour objectif d'expliquer les principes fondamentaux de l'ultrason au contraste, et de décrire les principales applications vasculaires de celle-ci (CEUS).

[Catheter-based treatment for acute deep vein thrombosis]. / Traitement percutané de la thrombose veineuse profonde aiguë.

Nearly half of patients with acute lower limb deep vein thrombosis (DVT) develop a post-thrombotic syndrome (PTS). This risk is particularly high in case of proximal DVT of the common femoral and iliac vein, the major lower limbs venous outflow vessel. Several studies have demonstrated that PTS incidence can be reduced with early vein recanalisation. Currently, catheter-based recanalisation therapies can be offered to selected patients with acute ilio-femoral deep vein thrombosis. Aim of the present article is to summarize current knowledge on these catheter-based recanalisation therapies.

[Non atherosclerotic arterial disease of lower limbs]. / Artériopathies non athéromateuses des membres inférieurs.

Non atherogenic peripheral arterial diseases must be taken into consideration whenever lower limb obstructive peripheral disease is diagnosed. This is particularly important in absence of classical cardiovascular risk factors. Management and treatment of these non atherogenic arterial disease are dependant on their causes.

The negative predictive value of D-dimer on the risk of recurrent venous thromboembolism in patients with multiple previous events: a prospective cohort study (the PROLONG PLUS study).

The optimal duration of anticoagulation after recurrent venous thromboembolism(VTE) is poorly established [1,2]. Recent studies suggested that D-dimer may identify patients at low risk of recurrence after a first VTE [3,4]. In a pilot, prospective, cohort study we aimed to assess the negative predictive value of D-dimer in patients with recurrent VTE. Patients with negative D-dimer while on treatment stopped anti coagulation and underwent repeated testing after 7, 15, and 30 days; treatment was resumed if D-dimer turned positive and permanently stopped if it remained negative. The study was interrupted after the enrolment of 75 patients. At that time, treating physicians decided treatment resumption in 12.2% of the patients, but the majority of events were distal or superficial vein thromboses. The rate of objectively documented recurrent proximal deep vein thrombosis (DVT) and/or pulmonary embolism (PE) was 2.56% (95% CI 0.13, 15.07%) in the 39 patients with persistently negative D-dimer at 30 days, for an annual incidence of VTE of 5.65 events/100 patient/years. These preliminary findings suggest that negative D-dimer may identify patients with history of previous VTE at low risk of recurrences, but this approach should be tested in larger trials in highly selected patients.

In postmenopausal women, lower limb peripheral arterial disease, assessed by ankle-brachial index, may be a strong predictor of cardiovascular risk.

BACKGROUND: Lower limb peripheral arterial disease (PAD) is a leading atherosclerotic disease in the elderly. However, awareness of the disease is poor, particularly in women. METHODS: In this retrospective, cross-sectional study, postmenopausal women referred to our Angiology Division were tested for PAD, defined as an "ankle-brachial index" (ABI) ≤0.9 or ≥1.4 (in the latter case with a "toe-brachial index" <0.7), or a history of lower limb arterial revascularization. Aim of our study was to assess cardiovascular (CV) risk profile in postmenopausal women with and without PAD, and to evaluate the role of PAD and six classic CV risk factors (CVRFs), namely age, current smoking, hypertension, dyslipidaemia, severe chronic renal failure, and diabetes in predicting CV disease (CVD), defined as coronary artery disease and/or cerebrovascular disease. RESULTS: Overall, 850 patients were included, 39.4% of whom with PAD. Compared with women without PAD, those with PAD were older (75.2 vs 66 years, respectively; p <0.001), and displayed higher rates of other CVRFs (p <0.001 for each). A personal history of CVD was reported in 18.8% of women with PAD and in 6.1% of those without PAD (p <0.001). At multivariate regression analysis, PAD (odds ratio [OR]: 2.15; 95% confidence interval [CI]: 1.33-3.47), and hypertension (OR: 2.20; 95%CI: 1.24-3.88) were the strongest factors associated with CVD presence. CONCLUSIONS: PAD is a strong marker of CVD in this selected series of postmenopausal women. If confirmed in the general population, PAD screening through ABI calculation may be considered for CV risk assessment in postmenopausal women.

Second consensus document on diagnosis and management of acute deep vein thrombosis: updated document elaborated by the ESC Working Group on aorta and peripheral vascular diseases and the ESC Working Group on pulmonary circulation and right ventricular function.

This consensus document is proposed to clinicians to provide the whole spectrum of deep vein thrombosis management as an update to the 2017 consensus document. New data guiding clinicians in indicating extended anticoagulation, management of patients with cancer, and prevention and management of post-thrombotic syndrome are presented. More data on benefit and safety of non-vitamin K antagonists oral anticoagulants are highlighted, along with the arrival of new antidotes for severe bleeding management.